This subtopic explores the integration of pharmacological interventions with person-centred dementia care, ensuring medication administration respects the
Topic Synopsis
This subtopic explores the integration of pharmacological interventions with person-centred dementia care, ensuring medication administration respects the individual's preferences, life history, and cognitive needs. It covers common medications such as cholinesterase inhibitors and memantine, their indications and side effects, and the critical role of collaborative decision-making involving the person, families, and multidisciplinary teams to optimise therapeutic outcomes while minimising distress.
Key Concepts & Core Principles
- Person-centred care: Tailoring support to the individual's preferences, history, and needs, rather than focusing solely on the condition.
- Types of dementia: Alzheimer's disease (most common, gradual onset), vascular dementia (caused by reduced blood flow to the brain), Lewy body dementia (with Parkinson-like symptoms), and frontotemporal dementia (affecting behaviour and language).
- The Mental Capacity Act 2005: A legal framework ensuring individuals are supported to make their own decisions where possible, with best interests decisions made for those lacking capacity.
- Communication techniques: Using simple language, non-verbal cues, validation therapy, and reminiscence to engage with individuals who have cognitive decline.
- Risk factors and prevention: Age, genetics, cardiovascular health, and lifestyle factors (e.g., diet, exercise, social engagement) that can influence dementia risk.
Exam Tips & Revision Strategies
- Always frame medication decisions within the person-centred values of respect, dignity, and empowerment—refer to case studies that illustrate how you would tailor administration.
- When discussing common medications, link each drug to the specific symptoms it targets (e.g., cognitive decline, agitation) and mention potential side effects that could impact quality of life.
- In written assignments, demonstrate knowledge of the legal frameworks (Mental Capacity Act, Deprivation of Liberty Safeguards) that underpin consent and covert medication.
- Prepare to explain how you would work with pharmacists, GPs, and care staff to regularly review medications, ensuring they remain appropriate as the condition progresses.
- When answering assessment questions or assignments, always explicitly link the choice of medication to the specific type and stage of dementia, supported by current NICE guidelines and best practice.
- Demonstrate a comprehensive understanding of person-centred care by discussing how to balance clinical needs with the individual’s personal history, preferences, and potential side effects, particularly in simplifying medication regimes.
- Use case study scenarios to showcase your ability to conduct a holistic assessment, identify risks like polypharmacy, and propose a clear, individualised medication management plan with appropriate monitoring.
- When discussing person-centred medication administration, always link back to the principles of the Mental Capacity Act and the importance of obtaining consent or acting in the person’s best interests.
Common Misconceptions & Mistakes to Avoid
- Assuming that all individuals with dementia will automatically benefit from anti-dementia drugs without considering individual health profiles or stage of dementia.
- Overlooking the importance of non-verbal cues and behavioural changes as indicators of pain or side effects, rather than conducting thorough checks.
- Failing to involve the individual and their family in decision-making, thus treating medication management as a purely clinical task.
- Not recognising that 'person-centred' does not mean simply asking preferences but adapting the entire approach to the person's cognitive abilities and communication style.
- Believing that medications can cure dementia, rather than primarily manage symptoms or slow progression.
- Assuming that all individuals with dementia lack the capacity to make decisions about their own medication; capacity is decision-specific and can fluctuate.
Examiner Marking Points
- Award credit for demonstrating an understanding of the main categories of dementia medications (e.g., donepezil, rivastigmine, galantamine, memantine) and their typical uses.
- Expect evidence of explaining how to obtain valid consent or act in the person's best interests when capacity is lacking, in line with the Mental Capacity Act.
- Look for practical strategies to support person-centred administration, such as using familiar routines, disguising medication in food only when prescribed, and monitoring for adverse effects.
- Credit should be given for showing how life history and behavioural symptoms influence medication reviews and non-pharmacological alternatives.
- Award credit for demonstrating accurate knowledge of common dementia medications, such as cholinesterase inhibitors (donepezil, rivastigmine, galantamine) and memantine, including their intended effects and typical stages of use.
- Award credit for explaining how a person-centred approach involves seeking informed consent, respecting the individual’s choices, and involving family members or advocates where appropriate, in line with the Mental Capacity Act.
- Award credit for describing the importance of holistic assessment before medication use, including consideration of non-pharmacological interventions, and the need for regular review to minimise inappropriate prescribing, especially of antipsychotics.
- Award credit for demonstrating an understanding of the main classes of medications used in dementia (e.g., cholinesterase inhibitors, NMDA receptor antagonists) and their indications for different types and stages of dementia.